(Q35808400)

10 August 2017

Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors (English)

1 reference

Erb-b2 receptor tyrosine kinase 2

10 August 2017

1 reference

1 reference

Ana Maria Gonzalez-Angulo

inferred from title

author

8

object named as

Ana M Gonzalez-Angulo

1 reference

10 August 2017

9

Gabriel N Hortobagyi

1 reference

10 August 2017

Naoki Niikura

1

1 reference

10 August 2017

Jun Liu

2

1 reference

10 August 2017

Naoki Hayashi

3

1 reference

10 August 2017

Elizabeth A Mittendorf

4

1 reference

10 August 2017

Yun Gong

5

1 reference

10 August 2017

Shana L Palla

6

1 reference

10 August 2017

Yutaka Tokuda

7

1 reference

10 August 2017

Naoto T Ueno

10

1 reference

10 August 2017

language of work or name

English

0 references

publication date

28 November 2011

1 reference

Journal of Clinical Oncology

10 August 2017

1 reference

10 August 2017

30

1 reference

10 August 2017

6

1 reference

10 August 2017

593-599

1 reference

Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Genome remodelling in a basal-like breast cancer metastasis and xenograft

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Breast tumor heterogeneity: cancer stem cells or clonal evolution?

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

HER-2/neu expression in primary and metastatic breast cancer

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295557

Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

25 September 2018

1 reference

12 December 2020

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

1 reference

12 December 2020

HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy

1 reference

12 December 2020

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

12 December 2020

Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis

1 reference

12 December 2020

HER2 status in a population-derived breast cancer cohort: discordances during tumor progression

1 reference

12 December 2020

c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues

1 reference

12 December 2020

Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study

1 reference

12 December 2020

Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer

1 reference

12 December 2020

HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process

1 reference

12 December 2020

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

1 reference

12 December 2020

Change of HER-2/neu status in a subset of distant metastases from breast carcinomas

1 reference

12 December 2020

The World Health Organization. Histological typing of breast tumors

1 reference

12 December 2020

Clonal heterogeneity in breast cancer: Karyotypic comparisons of multiple intra—and extra—tumorous samples from 3 patients

1 reference

12 December 2020

Nuclear structure in cancer tissues

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2010.33.8889

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

22124109

1 reference